Skip to main content

Advertisement

Table 1 Characteristics of studies included in the meta-analysis

From: Does overexpression of HER-2 correlate with clinicopathological characteristics and prognosis in colorectal cancer? Evidence from a meta-analysis

Study Year Country No. of patients Age (year) Technique Cut-off value No. of HER-2 Positive (%) Follow-up period (month) Outcome
Baiocchi 2009 Brazil 109 NA IHC >10 % Positive (%) 57.4 (median) OS
Chen 2010 China 44 55 (median) IHC 1+ 14 (31.8) 35 (median) OS, CP
Conradi 2013 Germany 264 63 (mean) IHC, S-ISH 2+ 70 (26.5) 48.5 (median) OS
Drecoll 2014 Switzerland 355 66 (median) IHC, FISH 2+ 51 (14.4) 87 (mean) OS
Ishida 2000 Japan 149 61.6 (mean) IHC NA 44 (29.5) NA OS, CP
Ismail 2007 Egypt 104 47.4 (mean) IHC 1+ 10 (9.6) 18 (median) OS, CP
Jesus 2005 Brazil 108 63.1 (mean) IHC >10 % 52 (48.1) 28.1 (mean) OS
Kavanagh 2009 Ireland 132 67.0 (mean) IHC, FISH 2+ 18 (13.6) NA OS
Lazaris 1995 Greece 60 68.75 (mean) IHC >10 % 21 (35) 60 (median) OS, CP
Li 2011 China 317 57.8 (mean) IHC 2+ 49 (15.5) 68.8 (median) OS, CP
Lim 2013 South Korea 95 69 (median) IHC, FISH 2+ 23 (24.2) 22.7 (median) OS, CP
Lu 2012 China 126 NA IHC >25 % 59 (46.8) NA OS, CP
Mckay 2002 UK 248 NA IHC 2+ 203 (81.9) 43 (median) OS, CP
Osako 1998 Japan 146 65.0 (mean) IHC NA 100 (68.5) 55.2 (median) OS, CP
Pappas 2013 Greece 51 70.9 (mean) IHC 2+ 2 (3.9) 18 (median) OS, CP
Park 2007 South Korea 137 62.4 (mean) IHC, FISH 2+ 65 (47.4) 48.5 (median) OS, CP
Rossi 2002 USA 156 75 (median) IHC 1+ 24 (15.4) 46.8 (median) OS
Shin 2014 Korea 266 63 (mean) IHC 2+ 80 (30.1) NA OS, CP
  1. IHC immunohistochemistry, S-ISH silver in situ hybridization, FISH fluorescence in situ hybridization, NA not applicable, OS overall survival, CP Clinicopathological parameters